The safety of metoclopramide use in the first trimester of pregnancy.
about
EUROmediCAT signal detection: an evaluation of selected congenital anomaly-medication associationsExposure to folic acid antagonists during the first trimester of pregnancy and the risk of major malformations.Managing hyperemesis gravidarum: a multimodal challenge.Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists.Pregnancy-related liver disorders.Nausea and vomiting of pregnancy.Optimal management of nausea and vomiting of pregnancy.Severe akathisia as a side effect of metoclopramide.Review of NVP and HG and Early Pharmacotherapeutic InterventionHigher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study.Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects.Treatment of nausea in pregnancy: a cross-sectional multinational web-based study of pregnant women and new mothers.The fetal safety of clomiphene citrate: a population-based retrospective cohort study.Fetal safety of macrolidesChallenges in interventional radiology: the pregnant patientMigraine therapy during pregnancy and lactation.Hyperemesis gravidarum: pathogenesis and the use of antiemetic agents.The clinical management of hyperemesis gravidarum.Assaying embryotoxicity in the test tube: current limitations of the embryonic stem cell test (EST) challenging its applicability domain.Management of gastrointestinal and liver diseases during pregnancy.Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation.Management and controversies of classical Hodgkin lymphoma in pregnancy.Tyrosine kinase-targeting drugs-associated heart failure.Management of Hematologic Malignancies: Special Considerations in Pregnant Women.Nausea and vomiting of pregnancy - What's new?Treatment options for hyperemesis gravidarum.Treatment of nausea and vomiting during pregnancy -a cross-sectional study among 712 Norwegian women.Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring.Metoclopramide in pregnancy: no association with adverse fetal and neonatal outcomes.Investigation of developmental toxicity and teratogenicity of antiemetics on rat embryos cultured in vitro.The safety of fetal exposure to proton-pump inhibitors during pregnancy.Safety considerations surrounding use of treatment options for nausea and vomiting in pregnancy.Exposure to nitrofurantoin during the first trimester of pregnancy and the risk for major malformations.Vomiting in pregnancy is associated with a higher risk of low birth weight: a cohort study.Which drug is effective and safe for acute malaria in pregnancy? Reviewing the evidenceDrug development for use during pregnancy: impact of the placentaSafety Profile of Drug Use During Pregnancy at Peripheral Health Centres in Burkina Faso: A Prospective Observational Cohort Study
P2860
Q28817912-C863DD11-0D75-48E6-A678-5AD7B4FCDB27Q33608040-2FB8CED4-84FA-448E-A2D2-CBA71364D4EDQ33633388-D1937F98-3808-4DBC-AFC2-F03AF114596AQ33827209-DDD2F0A1-35B0-436C-9D86-5CBE1A10243CQ33978151-F1E6C852-939A-4F6D-BACA-EFDE75B67769Q34027013-272206B7-DD31-47ED-B2F1-151880870578Q34345604-F60C6CB1-1831-4EE9-B627-97ACBEF900CDQ34361811-3A0F9F12-79E7-4FC5-A8EF-84E02D8E7B4CQ35608888-BF779C5E-C8B7-417F-9746-F0D3482BB279Q35664040-F9C54A7B-2D02-4339-9D98-4666EAC0A9B6Q35820722-4F021CDC-9096-40C5-8C88-E93F153142C3Q35858260-D4163B67-E3D7-48EA-B8BD-58B7A0F67C2DQ36320450-DB3B826C-6584-425D-B148-24C7587DDE0FQ36969814-5695B714-7B0E-4AF9-9469-E9330E4BB57DQ37329873-806772F6-8AE2-4879-B079-C768E95A697FQ37775960-E68BA721-B248-4CBE-9E2D-DAEF6363A22CQ37848438-2C2DFC6B-65E4-4FAC-BADF-E17E851D6078Q37855635-15A6D3C2-6658-4AAB-B23A-CD3878C6120BQ38003481-6BD33931-9C7C-451D-80B6-F950DDB4849CQ38178818-270D512B-6042-45CF-8AFF-FCBDD62226FEQ38246990-D40F4EDF-BBAA-4DFA-9877-95582839C434Q38356460-3E7F20D1-8EAC-426B-8076-9E5DD8696AF9Q38401605-152BF79B-25E8-43EC-8F06-DC603AB37DDEQ38594889-5A684F63-3C6E-456F-9BE4-BF2C3F115E83Q38840953-B715A791-46D1-405F-B49E-61A8C67F590EQ39077715-7EB32B2F-4C87-40C0-B556-6CC9B28EE880Q40055374-9E6C6CA4-7370-4012-9303-F99C5E486888Q41652270-D792E09A-65FB-421D-9FF6-25D4D960CE2CQ43411725-EF3A35DC-3755-4188-9105-67E41CFC044FQ44611128-9AC2AFCF-041E-492C-BD23-9438232B120EQ46326077-87742304-17ED-454F-A552-BA902BC7EC97Q47555157-B7B5A22E-6121-405F-A941-378851BCC876Q47826642-8A9FF84A-5B0C-44E9-B77F-910C96EBBC75Q55040035-92E1F6C5-A4E3-433A-B272-76E898D3FED9Q57013833-C4E22301-B602-4DA0-8862-EB4794AF8DBAQ58392274-E244E9E6-974A-46AE-BFEF-451FACBC85CEQ58698512-7CF38FA4-AF65-48A7-BE9B-5DFDCD9A19A3
P2860
The safety of metoclopramide use in the first trimester of pregnancy.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The safety of metoclopramide use in the first trimester of pregnancy.
@ast
The safety of metoclopramide use in the first trimester of pregnancy.
@en
The safety of metoclopramide use in the first trimester of pregnancy.
@nl
type
label
The safety of metoclopramide use in the first trimester of pregnancy.
@ast
The safety of metoclopramide use in the first trimester of pregnancy.
@en
The safety of metoclopramide use in the first trimester of pregnancy.
@nl
prefLabel
The safety of metoclopramide use in the first trimester of pregnancy.
@ast
The safety of metoclopramide use in the first trimester of pregnancy.
@en
The safety of metoclopramide use in the first trimester of pregnancy.
@nl
P2093
P356
P1476
The safety of metoclopramide use in the first trimester of pregnancy.
@en
P2093
Amalia Levy
Arnon Wiznitzer
Gideon Koren
Ilan Matok
Rafael Gorodischer
P304
P356
10.1056/NEJMOA0807154
P407
P577
2009-06-01T00:00:00Z